By Fineline Cube Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and GemPharmatech Inc. (SHA: 688046) officially signed a long‑term strategic cooperation agreement, the companies announced. The two companies will deepen their preclinical collaboration on small nucleic acid therapeutics across neurology, metabolism, and autoimmunity, while jointly building a closed‑loop R&D system spanning antibody discovery through preclinical optimization.
Deal Overview
| Item | Detail |
|---|---|
| Parties | Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) × GemPharmatech Inc. (SHA: 688046) |
| Deal Type | Long‑term strategic cooperation agreement |
| Signing Date | 20 Jul 2026 |
| Therapeutic Focus | Neurology, metabolism, and autoimmunity |
| Modality Focus | Small nucleic acid therapeutics; antibody and AOC molecules |
| Scope | Preclinical collaboration, joint R&D, and joint commercialization |
Deepening Preclinical Collaboration in Small Nucleic Acid Therapeutics
The two companies will deepen their preclinical collaboration on small nucleic acid therapeutics across neurology, metabolism, and autoimmunity, continuously optimizing:
- Model stability
- Evaluation consistency
- Clinical translational value
Both parties will mutually open access to high‑quality domestic and overseas client resources, project demands, and commercial opportunities, establishing a collaborative mechanism based on:
| Mechanism Element | Description |
|---|---|
| Shared Clients | Mutual access to each party’s client base |
| Cross‑Project Recommendations | Referral of project demands across both organizations |
| Shared Business Opportunities | Joint pursuit of commercial opportunities |
| Mutual Benefit | Contribution‑based value sharing |
Joint Antibody Screening and Molecular Optimization
The partnership defines complementary division of responsibilities:
| Sun‑Novo | GemPharmatech |
|---|---|
| Molecular design for small nucleic acids and other therapeutics | Antibody discovery |
| – | High‑throughput screening |
| – | In vivo efficacy validation |
| – | Druggability assessment |
Together, they will build a closed‑loop R&D system spanning:
Antibody discovery → AOC design → in vitro screening → in vivo validation → preclinical optimization
Joint Commercialization and Revenue Sharing
Both parties will jointly commercialize co‑developed antibody molecules, AOC molecules, and efficacy models through:
- Licensing out
- Technology transfers
- Co‑development
Revenue sharing will follow fair and transparent contribution‑based principles, with the following components agreed upon on a project‑by‑project basis:
| Component | Basis |
|---|---|
| Upfront payments | Per‑project agreement |
| Milestone payments | Per‑project agreement |
| Sales royalties | Per‑project agreement |
| Business development commissions | Per‑project agreement |
Strategic Rationale & Market Impact
- Small Nucleic Acid Convergence: The agreement positions two listed Chinese CRO/biotech players to combine forces in small nucleic acid therapeutics — one of the fastest‑growing modalities in drug development — across three high‑value chronic disease areas.
- Closed‑Loop R&D Efficiency: By linking antibody discovery, AOC design, in vitro screening, in vivo validation, and preclinical optimization into a single integrated system, the partnership aims to shorten discovery‑to‑candidate timelines and improve translational predictability.
- AOC Modality Focus: The explicit emphasis on AOC (antibody‑oligonucleotide conjugate) design reflects growing industry interest in targeted oligonucleotide delivery — a key enabling approach for expanding nucleic acid drugs into new tissues and indications.
- Built‑In Commercial Pathway: Unlike pure research collaborations, the agreement embeds joint commercialization via licensing, technology transfers and co‑development, with contribution‑based revenue sharing — creating direct monetization routes for co‑developed assets.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the partnership’s research collaboration, platform development, and commercialization outcomes. Actual results may differ due to risks including project execution, market conditions, and competitive dynamics.-Fineline Info & Tech